Loading clinical trials...
Loading clinical trials...
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Conditions
Interventions
Gemcabene
Placebo
Locations
24
United States
Central Research Associates, Inc.
Birmingham, Alabama, United States
Westside Medical Associates of Los Angeles
Beverly Hills, California, United States
National Research Institute
Huntington Park, California, United States
National Research Institute
Los Angeles, California, United States
Atlantic Clinical Research Collaborative- Cardiology
Atlantis, Florida, United States
Excel Medical Clinical Trials
Boca Raton, Florida, United States
Start Date
November 1, 2016
Primary Completion Date
June 1, 2017
Completion Date
August 1, 2017
Last Updated
June 25, 2020
NCT07307989
NCT03856476
NCT01890889
NCT00408382
NCT00347217
NCT01354327
Lead Sponsor
NeuroBo Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions